Irritable Bowel Syndrome - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Irritable Bowel Syndrome - Pipeline Review, H2 2018’, provides an overview of the Irritable Bowel Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome

- The report reviews pipeline therapeutics for Irritable Bowel Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Irritable Bowel Syndrome therapeutics and enlists all their major and minor projects

- The report assesses Irritable Bowel Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma PLC

Allergan Plc

Ardelyx Inc

Boston Pharmaceuticals Inc

ConSynance Therapeutics Inc

Cosmo Pharmaceuticals NV

Dong-A ST Co Ltd

Eisai Co Ltd

Enterome Bioscience ...

4D Pharma PLC

Allergan Plc

Ardelyx Inc

Boston Pharmaceuticals Inc

ConSynance Therapeutics Inc

Cosmo Pharmaceuticals NV

Dong-A ST Co Ltd

Eisai Co Ltd

Enterome Bioscience SA

ImmuneBiotech AB

Ironwood Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Merck & Co Inc

Metacrine Inc

Napo Pharmaceuticals Inc

Nextbiotix SAS

Protagonist Therapeutics Inc

RaQualia Pharma Inc

RedHill Biopharma Ltd

Sumitomo Dainippon Pharma Co Ltd

Synthetic Biologics Inc

Vitality Biopharma Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Irritable Bowel Syndrome - Overview 6

Irritable Bowel Syndrome - Therapeutics Development 7

Irritable Bowel Syndrome - Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 5

Irritable Bowel Syndrome - Overview 6

Irritable Bowel Syndrome - Therapeutics Development 7

Irritable Bowel Syndrome - Therapeutics Assessment 15

Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 23

Irritable Bowel Syndrome - Drug Profiles 34

Irritable Bowel Syndrome - Dormant Projects 113

Irritable Bowel Syndrome - Discontinued Products 117

Irritable Bowel Syndrome - Product Development Milestones 118

Appendix 127

List of Tables

List of Tables

Number of Products under Development for Irritable Bowel Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Tables

Number of Products under Development for Irritable Bowel Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Irritable Bowel Syndrome - Pipeline by 4D Pharma PLC, H2 2018

Irritable Bowel Syndrome - Pipeline by Allergan Plc, H2 2018

Irritable Bowel Syndrome - Pipeline by Ardelyx Inc, H2 2018

Irritable Bowel Syndrome - Pipeline by Boston Pharmaceuticals Inc, H2 2018

Irritable Bowel Syndrome - Pipeline by ConSynance Therapeutics Inc, H2 2018

Irritable Bowel Syndrome - Pipeline by Cosmo Pharmaceuticals NV, H2 2018

Irritable Bowel Syndrome - Pipeline by Dong-A ST Co Ltd, H2 2018

Irritable Bowel Syndrome - Pipeline by Eisai Co Ltd, H2 2018

Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H2 2018

Irritable Bowel Syndrome - Pipeline by ImmuneBiotech AB, H2 2018

Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals Inc, H2 2018

Irritable Bowel Syndrome - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018

Irritable Bowel Syndrome - Pipeline by Merck & Co Inc, H2 2018

Irritable Bowel Syndrome - Pipeline by Metacrine Inc, H2 2018

Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, H2 2018

Irritable Bowel Syndrome - Pipeline by Nextbiotix SAS, H2 2018

Irritable Bowel Syndrome - Pipeline by Protagonist Therapeutics Inc, H2 2018

Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc, H2 2018

Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd, H2 2018

Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2018

Irritable Bowel Syndrome - Pipeline by Synthetic Biologics Inc, H2 2018

Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, H2 2018

Irritable Bowel Syndrome - Dormant Projects, H2 2018

Irritable Bowel Syndrome - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Irritable Bowel Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Figures

Number of Products under Development for Irritable Bowel Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports